BCRX — Q4 FY25 Earnings Review

Date: 2026-04-06 Quarter: Q4 FY25 (Dec-2025) | Reported: Feb 26, 2026 Market cap: $2.0B | Run-rate P/S (ex-license): 3.1x | EV/FY26E Non-GAAP OI: 11.4x

Verdict

BCRX does not belong in a concentrated growth portfolio. Full stop. FY2025 was the capstone — first-ever full-year profitability, $601.8M ORLADEYO (+43% ex-Europe), $214M Non-GAAP OI. Excellent execution. But forward growth is 12.8% normalised. That's a mature franchise, not a compounder. Navenibart (approval ~late 2028) is a 2.5-year call option, not a near-term catalyst. At 3.1x P/S and 11.4x EV/Non-GAAP OI, the stock is fairly priced for what it is — but what it is doesn't fit my framework.

I haven't written about BCRX before, but applying my framework: growth deceleration from 37-43% to 12.8% is a disqualifier. You cannot dress this up. The EU divestiture explains it, but that doesn't change the forward math.

Atlas scored this at Conviction 2/5. I concur. The only path to re-rating is navenibart Phase 3 success — and that's 2028. I'm not paid to wait.

The Numbers

Revenue — 16 Quarters

| | Q1_22 | Q2_22 | Q3_22 | Q4_22 | Q1_23 | Q2_23 | Q3_23 | Q4_23 | Q1_24 | Q2_24 | Q3_24 | Q4_24 | Q1_25 | Q2_25 | Q3_25 | Q4_25 | | | Mar-22 | Jun-22 | Sep-22 | Dec-22 | Mar-23 | Jun-23 | Sep-23 | Dec-23 | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---| | Rev ($m) | 49.9 | 65.5 | 75.8 | 79.5 | 68.8 | 82.5 | 86.7 | 93.4 | 92.8 | 109.3 | 117.1 | 131.5 | 145.5 | 163.4 | 159.4 | 406.6* | | YoY % | — | — | — | — | +38% | +26% | +14% | +18% | +35% | +33% | +35% | +41% | +57% | +50% | +36% | +209%* | | QoQ % | — | +31% | +16% | +5% | -14% | +20% | +5% | +8% | -1% | +18% | +7% | +12% | +11% | +12% | -2% | +155%* |

* Q4_FY25 total inflated by 244Mone − timeEuropeanORLADEYOlicensefee. * *Underlyingquarterlyrevenue : **162.6M (+23.7% YoY).

ORLADEYO — The Real Business

Q4_FY25 ORLADEYO declined -4.7% sequentially. Management says this is the EU divestiture mid-quarter (October). Probably true — prior quarters included EU revenue, Q4 is US-only. But I can't verify the US-only underlying trend without the split. Record new Rx claims are qualitative. I need Q1 FY26 to confirm.

Annual ORLADEYO Trajectory — This Is the Story

Three years of acceleration: +30% → +34% → +38%/+43%. Then the wall: +12.8%. Even if management sandbagged FY26 the same way they sandbagged FY25 (initial beat was +10.9%), you'd get ~$700M → +24% vs ex-EU. Better, but still decelerating hard.

→ Growth trajectory: Decelerating. Not ambiguous. Not temporary. Structural.

Margin Trajectory

* Q4 Non-GAAP margin on ex-license revenue base ($162.6M).

Gross margins ~97% — pharma-grade. No issue. This is a molecule with negligible COGS.

Non-GAAP operating margin expanded beautifully through FY2025: 12.8% → 29.3% → 34.9% → 32.4% → 38.4%. FY2025 Non-GAAP OI total: $214.2M (+240% YoY). Genuine operating leverage.

But FY2026 reverses the trend. Implied Non-GAAP OI: ~$187.5M (midpoint), -12% YoY. Navenibart Phase 3 costs + Astria integration costs eat into margins. Non-GAAP OpEx guided 450 − 470MvsFY2025 395M = +14-19% OpEx growth on 5-13% revenue growth.

→ Margin trajectory: Inflected positively in FY2025, compressing in FY2026. Not the direction I want to see.

Leading Indicators

The leading indicator picture is thin. This isn't a SaaS company with RPO, ARR, billings, and customer cohorts. The leading indicators are qualitative — "record NRx," "expanding prescriber base," "persistence rates." I can't build a predictive model from this. And management stopped disclosing absolute patient counts after Q4 FY23. When companies stop giving you a KPI, it's usually because the KPI stopped being flattering.

→ No divergence signal. Leading indicators are directionally positive but lack the quantitative specificity I demand.

Guidance & Beat History

Management credibility: High. FY2025 initial guide was sandbagged by nearly 11%. Raised three times through the year. Beat all four milestones. If they do the same in FY2026, actual ORLADEYO could be ~$700M. But that's speculative — I don't invest on "they might be sandbagging."

FY2026 guidance pattern: Beat-and-guide-lower (structurally). FY2025 Non-GAAP OI was 214.2M.FY2026impliedNon − GAAPOIis 187.5M. Revenue grows, profitability declines. This is the navenibart investment thesis in action — management is deliberately spending profits on the Phase 3 program. Rational capital allocation if navenibart works. Value destruction if it doesn't.

Balance Sheet & Capital Structure

The good: Term loan gone. Clean balance sheet transformation. Cash essentially flat year-over-year despite repaying $315M of debt — funded by the EU divestiture proceeds.

The ugly: ~866Minnon − equityclaims(465.7M royalty + $400M Blackstone facility) against a 2.0Bmarketcap.TheroyaltyobligationisaperpetualtaxonORLADEYOcashflows, declining 48M/year but still material.

SBC & Dilution

SBC grew 30% YoY — faster than ORLADEYO ex-EU revenue (+43%, but slowing to 12.8%). SBC as a percentage of revenue isn't declining. Dilution of 18.6% over 4 years = ~4.4% annualised. Acceptable, but watch the FY2026 trajectory — if revenue growth slows to 13% while SBC keeps growing 20%+, this ratio worsens fast.

Valuation (Run-Rate)

At 3.1x P/S with 12.8% growth, PEG is 0.24x — optically cheap. But PEG is misleading for low-growth companies. A 12.8% grower at 3.1x P/S is what the market pays for a mature pharma franchise with single-product risk and a $466M royalty overhang. This isn't cheap — it's appropriately priced.

If navenibart succeeds (late 2028): Additional $500M+ revenue potential from ~5,000 US injectable prophylaxis patients. That could re-rate the multiple to 4-5x P/S → $3B+ market cap. A double from here. But that's a 2028-2029 story with binary clinical risk.

Analyst consensus: $20.55 PT (>100% upside) — they're pricing in full navenibart success. The market isn't.

Atlas Comparison

Atlas scored this 2/5 conviction, CONDITIONAL PASS on the growth gate. I agree. Our frameworks align on the core issue: forward growth fails the threshold. Where I push harder:

1. The patient count disclosure gap is more concerning than Atlas flagged. 1,104 patients was the last disclosed figure (Q4 FY23). Two years of silence. That's not accidental.
2. Non-GAAP OI declining FY25→FY26 is a red flag Atlas acknowledged but underweighted. Growth decelerating AND margins compressing is the double-warning pattern from my framework.
3. SBC running at 15% of revenue with no improving trend — Atlas mentioned it; I'd emphasize it's higher than it looks because the growth rate of SBC (30%) is outpacing revenue growth going forward.

Where Atlas had it right and I add nothing new: scuttlebutt findings (competitive resilience, employee sentiment, clinical data quality), valuation context, and the navenibart optionality framing. Atlas's six-factor scoring was clean.

Thesis Assessment

Thesis: BCRX is a profitable rare disease franchise with pipeline optionality, not a growth stock.

Thesis status: Not a candidate. This is a GARP/pharma value play, not a growth portfolio holding. The operational execution is genuinely impressive — first-ever profitability, debt-free, pipeline investment funded non-dilutively. But growth investors need growth. 12.8% doesn't qualify.

What I'd Need to Change My Mind

1. FY2026 organic ORLADEYO growth re-accelerates to 20%+ (Q1+Q2 FY26 ORLADEYO sequential adds of $8-10M/Q, implying $640M+ run rate by mid-year)
2. Navenibart Phase 3 interim data shows >90% attack reduction (de-risks the 2028 approval)
3. Management resumes disclosing absolute patient counts — and they're growing >15% annually
4. FY2026 guidance meaningfully raised by Q2 earnings (not just a token $5-10M raise)

Without at least two of these, BCRX stays on the sidelines.

Action

No position. Not a buy. Fascinating company, excellent management, wrong growth profile. For a pharma-specialist investor, this is probably compelling at 10-11x Non-GAAP OI with navenibart upside. For a concentrated growth investor running 7-12 positions with 75-85% in the top 5? Not a chance.

-wsm

(No position in BCRX)